SAN RAMON, Calif., January 20, 2020—CooperVision has named Jane Agbontaen as Senior Brand Director for Myopia Management – Americas. In this newly created role, Agbontaen will be responsible for the strategic planning and execution of all activities that support the U.S. growth of CooperVision’s myopia management portfolio – specifically the Brilliant Futures™ Myopia Management Program with MiSight® 1 day, the first and only FDA-approved product1 clinically proven to slow the progression of myopia when initially prescribed for children 8-12 years old* in the United States.
Agbontaen’s role includes cross-functional and cross-business support to ensure CooperVision’s MiSight® 1 day commercialization strategy is successful. Growing the portfolio includes touchpoints with eyecare practitioners and patients, as well as healthcare and legislative ecosystems that govern children’s health and wellness.
“With the FDA approval of MiSight® and the impending roll out of our Brilliant Futures™ Myopia Management Program, we require an evolution of our sales and marketing approach as we take on the rising epidemic of childhood myopia. Going forward, broadening our scope of healthcare provider alliances and industry partnerships are essential elements of shaping the standard of care in myopia management,” said Simon Seshadri, Vice President of Marketing at CooperVision, North America. “Jane’s previous experiences and skills are a perfect fit for this role and to help us achieve our desired outcomes. I’m delighted to have her onboard.”
Agbontaen has more than 20 years of professional experience in the healthcare space and with large medical device players such as Hologic, Abbot Medical Optics and Johnson & Johnson DePuy Synthes. While at Abbot Medical Optics, which was acquired by Johnson & Johnson Vision Care during her tenure, Agbontaen managed a broad brand portfolio in the cataracts segment, including intraocular lenses and instruments. Agbontaen received her bachelor’s degree from Long Island University and her MBA from the Stern School at New York University.
# # #
MiSight® 1 day contact lenses are currently approved for sale in the United States, Canada, the United Kingdom, France, Spain, Portugal, Netherlands, Belgium, Germany, Austria, Switzerland, the Nordic Region, Chile, Israel, Singapore, Malaysia, Hong Kong, Australia and New Zealand. MiSight® 1 day is not approved in Japan.
1 MiSight® (omafilcon A) daily wear single use Soft Contact Lenses are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
* when compared to the children in the control group wearing a single vision 1-day contact lens.
About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of daily disposable, two-week and monthly contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism, presbyopia and childhood myopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Media Contacts
Consumer Media:
EvolveMKD, CooperVision@EvolveMKD.com or +1-646-517-4220
Eyecare, Medical and Science Media:
McDougall Communications, jamie@mcdougallpr.com or +1-585-478-4338 (mobile)